Intensity Therapeutics (INTS) investor relations material

Executive summary

• Focused on late-stage clinical development of INT230-6, a novel intratumoral cancer therapy, with ongoing and paused Phase 2 and 3 trials due to funding constraints; protocol amendment and enrollment restart for INVINCIBLE-4 Study in Q1 2026.

• No revenue generated to date; operations funded primarily through equity and convertible note offerings.

• Net loss for the nine months ended September 30, 2025 was $8.6 million, with an accumulated deficit of $75.3 million.

• Cash and cash equivalents as of September 30, 2025 were $7.1 million, with an additional $6 million raised post-quarter, totaling $13.6 million raised since Q3 2025.

• Published IT-01 Study results showing strong disease control and survival in advanced cancers.

Financial highlights

• Research and development expenses for the nine months ended September 30, 2025 were $5.3 million, down 38% year-over-year; Q3 2025 R&D expenses were $1.6 million, down from $2.2 million in Q3 2024.

• General and administrative expenses for the same period were $3.5 million, down 27% year-over-year; Q3 2025 G&A expenses were $1.2 million, down from $1.4 million in Q3 2024.

• Net loss for the nine months ended September 30, 2025 was $8.6 million, an improvement from $13.1 million in the prior year period; Q3 2025 net loss was $2.7 million, compared to $3.5 million in Q3 2024.

• Weighted average shares outstanding increased significantly to 43.0 million in Q3 2025 from 13.8 million in Q3 2024 due to equity issuances.

• Cash and cash equivalents totaled $7.1 million as of September 30, 2025.

Outlook and guidance

• Sufficient cash runway projected through the end of Q1 2027, supporting ongoing and planned clinical activities.

• Plans to restart paused clinical trials, including INVINCIBLE-4 in Q1 2026 and INVINCIBLE-3 once funding is secured.

• Substantial doubt remains about ability to continue as a going concern without additional capital.